RIPE-KG · Version 1.1.0 · Resource

ripekg:work/10.1097%2Fhs9.0000000000000881

https://w3id.org/ripe/ripe-kg/work/10.1097%2Fhs9.0000000000000881
SubjectPredicateObject
ripekg:work/10.1097%2Fhs9.0000000000000881NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma prism:doi 10.1097/hs9.0000000000000881
ripekg:work/10.1097%2Fhs9.0000000000000881NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma dcterms:title NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
ripekg:work/10.1097%2Fhs9.0000000000000881NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma rdf:type node1
ripekg:work/10.1097%2Fhs9.0000000000000881NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma rdf:type http://purl.org/spar/fabio/Work
ripekg:work/10.1097%2Fhs9.0000000000000881NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma rdf:type rdfs:Resource
ripekg:work/10.1097%2Fhs9.0000000000000881NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma rdf:type owl:Thing
ripekg:work/10.1097%2Fhs9.0000000000000881NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma rdf:type prov:Entity
ripekg:work/10.1097%2Fhs9.0000000000000881NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma rdf:type ripe:WorkWork
ripekg:work/10.1097%2Fhs9.0000000000000881NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma owl:sameAs https://semopenalex.org/work/W4367693126
ripekg:work/10.1136%2Fbmj-2025-084314Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial http://purl.org/spar/cito/cites ripekg:work/10.1097%2Fhs9.0000000000000881NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma